Literature DB >> 24691649

The economic burden of fracture patients with osteoporosis in western China.

B Qu1, Y Ma, M Yan, H-H Wu, L Fan, D-F Liao, X-M Pan, Z Hong.   

Abstract

UNLABELLED: To study the cost of osteoporotic fracture in China, we performed a prospective study and compared the costs of the disease in referral patients with fractures in three of the most common sites. Our results indicated that the economic burden of osteoporotic fracture to both Chinese patients and the nation is heavy.
INTRODUCTION: This paper aims to study the cost of osteoporotic fracture in China and thus to provide essential information about the burden of this disease to individuals and society.
METHODS: This prospective observational data collection study assessed the cost related to hip, vertebral, and wrist fracture 1 year after the fracture based on a patient sample consisting of 938 men and women. Information was collected using patient records, registry sources, and patient interviews. Both direct medical, direct non-medical, and indirect non-medical costs were considered.
RESULTS: The annual total costs were highest in hip fracture patients (renminbi, RMB 27,283 or USD 4,330, with confidence interval (RMB 25715, 28851)), followed by patients with vertebral fracture (RMB 21,474 or USD 3,409, with confidence interval (RMB 20082, 22866)) and wrist fracture (RMB 8,828 or USD 1,401, with confidence interval (RMB 7829, 9827)). The direct medical care costs averaged approximately RMB 17,007 per year per patient, of which inpatient costs, drugs, and investigations accounted for the majority of the costs. Nonmedical direct costs were much less compared to direct healthcare costs and averaged approximately RMB 1,846.
CONCLUSION: These results indicate that the economic burden of osteoporotic fracture to both Chinese patients and China was heavy, and the proportion of the costs in China demonstrated many similar features and some significant differences compared to other countries.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24691649     DOI: 10.1007/s00198-014-2699-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  20 in total

1.  Epidemiology, treatment and costs of osteoporosis in Germany--the BoneEVA Study.

Authors:  B Häussler; H Gothe; D Göl; G Glaeske; L Pientka; D Felsenberg
Journal:  Osteoporos Int       Date:  2006-09-19       Impact factor: 4.507

2.  Costs and quality of life associated with osteoporosis-related fractures in Sweden.

Authors:  Fredrik Borgström; Niklas Zethraeus; Olof Johnell; Lars Lidgren; Sari Ponzer; Olle Svensson; Peter Abdon; Ewald Ornstein; Karl Lunsjö; Karl Göran Thorngren; Ingemar Sernbo; Clas Rehnberg; Bengt Jönsson
Journal:  Osteoporos Int       Date:  2005-11-09       Impact factor: 4.507

3.  Prevalence of osteoporosis and related risk factors in UK women in the seventh decade: osteoporosis case finding by clinical referral criteria or predictive model?

Authors:  P A Ballard; D W Purdie; C M Langton; S A Steel; S Mussurakis
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

4.  Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.

Authors:  Crystal Pike; Howard G Birnbaum; Matt Schiller; Hari Sharma; Russel Burge; Eric T Edgell
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis.

Authors:  J A Kanis; O Johnell; A Oden; B Jonsson; C De Laet; A Dawson
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

6.  Very low prevalence of hip osteoarthritis among Chinese elderly in Beijing, China, compared with whites in the United States: the Beijing osteoarthritis study.

Authors:  Michael C Nevitt; Ling Xu; Yuqing Zhang; Li-Yung Lui; Wei Yu; Nancy E Lane; Mingwei Qin; Marc C Hochberg; Steven R Cummings; David T Felson
Journal:  Arthritis Rheum       Date:  2002-07

7.  Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative.

Authors:  Z Chen; M Maricic; A K Aragaki; C Mouton; L Arendell; A M Lopez; T Bassford; R T Chlebowski
Journal:  Osteoporos Int       Date:  2008-09-03       Impact factor: 4.507

8.  Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden.

Authors:  Oskar Ström; Fredrik Borgstrom; Niklas Zethraeus; Olof Johnell; Lars Lidgren; Sari Ponzer; Olle Svensson; Peter Abdon; Ewald Ornstein; Leif Ceder; Karl Goran Thorngren; Ingemar Sernbo; Bengt Jonsson
Journal:  Acta Orthop       Date:  2008-04       Impact factor: 3.717

9.  The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture.

Authors:  F Borgström; I Lekander; M Ivergård; O Ström; A Svedbom; V Alekna; M L Bianchi; P Clark; M D Curiel; H P Dimai; M Jürisson; R Kallikorm; O Lesnyak; E McCloskey; E Nassonov; K M Sanders; S Silverman; M Tamulaitiene; T Thomas; A N A Tosteson; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2013-01-10       Impact factor: 4.507

10.  Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study.

Authors:  F Guillemin; L Martinez; M Calvert; C Cooper; T Ganiats; M Gitlin; R Horne; A Marciniak; J Pfeilschifter; S Shepherd; A Tosteson; S Wade; D Macarios; N Freemantle
Journal:  Osteoporos Int       Date:  2013-06-11       Impact factor: 4.507

View more
  46 in total

1.  Discovery of potential biomarkers for osteoporosis using LC-MS/MS metabolomic methods.

Authors:  J Wang; D Yan; A Zhao; X Hou; X Zheng; P Chen; Y Bao; W Jia; C Hu; Z-L Zhang; W Jia
Journal:  Osteoporos Int       Date:  2019-02-18       Impact factor: 4.507

Review 2.  Economic burden of osteoporosis-related hip fracture in Asia: a systematic review.

Authors:  N-A Mohd-Tahir; S-C Li
Journal:  Osteoporos Int       Date:  2017-03-17       Impact factor: 4.507

3.  Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model.

Authors:  L Si; T M Winzenberg; Q Jiang; A J Palmer
Journal:  Osteoporos Int       Date:  2015-01-08       Impact factor: 4.507

4.  Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.

Authors:  W Ni; Y Jiang
Journal:  Osteoporos Int       Date:  2016-08-31       Impact factor: 4.507

5.  Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population.

Authors:  Dan-Dan Yan; Jie Wang; Xu-Hong Hou; Yu-Qian Bao; Zhen-Lin Zhang; Cheng Hu; Wei-Ping Jia
Journal:  Acta Pharmacol Sin       Date:  2017-12-14       Impact factor: 6.150

6.  Increased risk of bone fracture among patients with urinary calculi: a nationwide longitudinal population-based study.

Authors:  S-M Ou; Y-T Chen; C-J Shih; D-C Tarng
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

7.  Association of adiposity indices with bone density and bone turnover in the Chinese population.

Authors:  J Wang; D Yan; X Hou; P Chen; Q Sun; Y Bao; C Hu; Z Zhang; W Jia
Journal:  Osteoporos Int       Date:  2017-05-29       Impact factor: 4.507

8.  MiR-351 negatively regulates osteoblast differentiation of MSCs induced by (+)-cholesten-3-one through targeting VDR.

Authors:  Qiuke Hou; Yongquan Huang; Yiwen Luo; Bin Wang; Yamei Liu; Rudong Deng; Saixia Zhang; Fengbin Liu; Dongfeng Chen
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

9.  Projection of osteoporosis-related fractures and costs in China: 2010-2050.

Authors:  L Si; T M Winzenberg; Q Jiang; M Chen; A J Palmer
Journal:  Osteoporos Int       Date:  2015-03-12       Impact factor: 4.507

10.  Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX.

Authors:  Yawen Jiang; Weiyi Ni
Journal:  J Bone Miner Metab       Date:  2015-11-20       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.